Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 7th Preview)
-
Servier shells out $2.5B for Day One – picks up pediatric glioma drug
Servier agreed to acquire Day One Biopharmaceuticals for roughly $2.5 billion in cash, buying the company’s marketed pediatric glioma therapy Ojemda (tovorafenib) and its development-stage oncology programs. The deal, announced March 6, offers Servier an immediate commercial foothold in rare pediatric brain tumors while augmenting its early- to late-stage oncology pipeline. Day One generated about $155 million in sales from Ojemda in 2025 and will be integrated into Servier’s rare‑cancer strategy. Servier said it will fund the purchase with a mix of cash and investments; the transaction carries an approximate 68% premium to Day One’s closing share price and is expected to close in Q2. Company statements highlight product synergies between Ojemda and Servier’s approved Voranigo, while analysts flagged potential upside from Day One’s ADC programs. The acquisition underscores continued buyer appetite for commercial-stage rare oncology assets that add near-term revenue and targeted R&D programs.
-
Prasad exits FDA in April — tenure marked by high‑profile clashes
Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), will leave the agency at the end of April after a contentious tenure characterized by stringent reviews and several high-profile drug rejections. Multiple outlets reported the departure and described how Prasad’s decisions on vaccines, gene and cell therapies—and his management moves—provoked industry and patient‑advocate pushback. Prasad’s leadership saw increased scrutiny of rare‑disease applications and a reworking of vaccine guidance; critics and supporters have both publicly debated whether his stricter posture reflects needed rigor or disruptive policy shifts. The FDA has not named a replacement; agency officials said the departure follows a planned leave-from-academia timeframe but noted the exit occurs amid ongoing regulatory tensions. Market and policy watchers flagged the move as a potential inflection point for CBER regulatory direction and stakeholder relations.
-
FDA doubles down: uniQure told to run sham‑controlled Huntington’s trial
The FDA told uniQure that a sham‑controlled randomized trial is required for its surgically delivered gene therapy AMT‑130 for Huntington’s disease, with an unnamed senior official clarifying that the control arm would include anesthesia and minor scalp nicks rather than a partial burr hole. The agency reiterated its reviewers’ request following uniQure’s public objections that a sham would pose undue risk to patients. UniQure had argued pivotal Phase 1/2 data—showing a 75% slowing of progression versus external controls—should suffice for a BLA submission; the FDA has said the Phase 1/2 study design is not adequate as primary evidence. The exchange highlights the agency’s insistence on randomized, internally controlled evidence for high‑risk neurosurgical biologics and signals continued friction over acceptable trial designs in rare neurodegenerative diseases.
-
Roche/Zealand amylin falls short — petrelintide’s weight loss underwhelms
Mid‑stage results for petrelintide, an amylin analog developed by Zealand with Roche, produced placebo‑adjusted weight loss of about 9.0% (10.7% mean reduction vs 1.7% placebo) at 42 weeks—below investor expectations and analyst benchmarks set by competing programs. The Phase 2 ZUPREME‑1 readout triggered a stock drop for Zealand while the company emphasized tolerability and a path to Phase 3. Roche and Zealand framed the data as demonstrating favorable safety and consistent efficacy, but analysts raised concerns about differentiation in a hypercompetitive obesity market where GLP‑1 and next‑gen candidates have set higher efficacy expectations. The results will shape dose selection and positioning ahead of planned Phase 3 work and underscore the escalating efficacy bar in anti‑obesity therapeutics.
-
FDA greenlights J&J Tecvayli‑Darzalex combo under priority pathway — approval comes fast
The FDA approved Johnson & Johnson’s Tecvayli plus Darzalex Faspro combination for previously treated multiple myeloma and converted Tecvayli’s accelerated monotherapy approval to full approval after the MajesTEC‑3 phase 3 confirmatory data showed an 83% reduction in progression or death. The agency used its Commissioner’s National Priority Voucher pilot to expedite review, issuing clearance about 55 days after submission. Regulators cited the magnitude of MajesTEC‑3’s benefit—high progression‑free and overall survival gains—as justification for rapid action. J&J moved quickly through supplemental filings and Real‑Time Oncology Review channels; the approval reshapes the second‑line myeloma landscape and may pressure competitors to accelerate combination strategies or new comparator trials.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.